NYSEMKT: CANF
Can Fite Biopharma Ltd Stock Ownership - Who owns Can Fite Biopharma?

Insider buying vs selling

Have Can Fite Biopharma Ltd insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when CANF insiders and whales buy or sell their stock.

CANF Shareholders

What type of owners hold Can Fite Biopharma Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Morgan Stanley0.00%32,512$39.01kInstitution
Rhumbline Advisers0.00%26,880$32.26kInstitution
Bnp Paribas Financial Markets0.00%25,185$30.22kInstitution
Two Sigma Securities LLC0.00%19,395$23.27kInstitution
Kohmann Bosshard Financial Services LLC0.00%3,401$4.08kInstitution
Fifth Third Bancorp0.00%3,000$3.60kInstitution
Wells Fargo Company0.00%2,500$3.00kInstitution
National Bank Of Canada0.00%600$720.00Institution
Citigroup Inc0.00%553$663.60Institution
Activest Wealth Management0.00%200$240.00Institution

1 of 2

CANF vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CANF0.00%0.00%
CRIS5.31%94.69%
RLYB43.21%56.79%
PSTV2.82%97.18%Net Buying
RLMD25.31%3.78%Net Buying

Can Fite Biopharma Stock Ownership FAQ

Who owns Can Fite Biopharma?

Can Fite Biopharma (NYSEMKT: CANF) is owned by 0.00% institutional shareholders, 0.00% Can Fite Biopharma insiders, and 100.00% retail investors. Morgan Stanley is the largest individual Can Fite Biopharma shareholder, owning 32,512.00 shares representing 0.00% of the company. Morgan Stanley's Can Fite Biopharma shares are currently valued at $40.31k.

If you're new to stock investing, here's how to buy Can Fite Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.